Patents by Inventor Everett Stone

Everett Stone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES FOR THERAPEUTIC USES
    Publication number: 20210380962
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 9, 2021
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett STONE, Wei-Cheng LU, Christos KARAMITROS
  • Administration of kynurenine depleting enzymes for tumor therapy
    Patent number: 11168142
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 9, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Nicholas Marshall, John Blazeck, Wei-Cheng Lu
  • Enzyme-mediated depletion of adenosine and/or methylthioadenosine
    Patent number: 11118167
    Abstract: Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: September 14, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett Stone, Donjeta Gjuka
  • ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
    Publication number: 20210213059
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: August 18, 2020
    Publication date: July 15, 2021
    Inventors: George GEORGIOU, Everett STONE
  • HUMAN KYNURENINASE ENZYME VARIANTS HAVING IMPROVED PHARMACOLOGICAL PROPERTIES
    Publication number: 20210207110
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: March 2, 2017
    Publication date: July 8, 2021
    Inventors: George GEORGIOU, Everett STONE, John BLAZECK
  • Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
    Patent number: 11033612
    Abstract: Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-?-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 15, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Wei-Cheng Lu
  • Compositions Of Engineered Human Arginases And Methods For Treating Cancer
    Publication number: 20210128703
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Applicant: Aerase, Inc.
    Inventors: George Georgiou, Everett Stone
  • ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE
    Publication number: 20210095264
    Abstract: Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: November 17, 2020
    Publication date: April 1, 2021
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett STONE, Donjeta GJUKA
  • ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE
    Publication number: 20210054350
    Abstract: Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: December 20, 2018
    Publication date: February 25, 2021
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett STONE, Donjeta GJUKA
  • Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
    Patent number: 10865403
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cancer and cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 15, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Shira Cramer
  • ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS
    Publication number: 20200338197
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: July 15, 2020
    Publication date: October 29, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: George GEORGIOU, Everett STONE
  • Administration of kynurenine depleting enzymes for tumor therapy
    Patent number: 10772913
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: September 15, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • Engineered primate L-methioninase for therapeutic purposes
    Patent number: 10724026
    Abstract: Methods and compositions relating to the engineering of an improved protein with methionine-?-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 28, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Wei-Cheng Lu
  • Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
    Patent number: 10716856
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: July 21, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20200224176
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 16, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • ENGINEERED ENZYMES WITH METHIONINE-GAMMA-LYASE ENZYMES AND PHARMACOLOGICAL PREPARATIONS THEREOF
    Publication number: 20200087706
    Abstract: Methods and composition related to the engineering of a novel protein with methionine-?-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Inventors: George GEORGIOU, Everett STONE
  • ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
    Publication number: 20200054674
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: April 2, 2019
    Publication date: February 20, 2020
    Inventors: George GEORGIOU, Everett STONE
  • ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS
    Publication number: 20200038511
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: June 13, 2019
    Publication date: February 6, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: George GEORGIOU, Everett STONE
  • Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
    Patent number: 10526638
    Abstract: Methods and composition related to the engineering of a novel protein with methionine-?-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: January 7, 2020
    Assignee: AEMase, Inc.
    Inventors: George Georgiou, Everett Stone
  • ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES
    Publication number: 20190390187
    Abstract: Methods and compositions relating to the engineering of an improved protein with methionine-?-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: February 1, 2019
    Publication date: December 26, 2019
    Applicant: Board of Regents, The University of Texas System
    Inventors: George Georgiou, Everett Stone, Wei-Cheng Lu